1-4 of 4
Sharon Sullivan
Close
Sort by
Journal Articles

Efficacy and Safety of Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma Naïve to B-Cell Maturation Antigen (BCMA)-Directed Therapies: Results from Cohort a of the Magnetismm-3 Study

Nizar Jacques Bahlis, Michael H. Tomasson, Mohamad Mohty, Ruben Niesvizky, Ajay K. Nooka, Salomon Manier, Christopher Maisel, Yogesh Jethava, Joaquin Martinez-Lopez, H Miles Prince, Bertrand Arnulf, Paula Rodriguez Otero, Guenther Koehne, Cyrille Touzeau, Noopur Raje, Shinsuke Iida, Marc-Steffen Raab, Eric Leip, Sharon Sullivan, Umberto Conte, Andrea Viqueira, Alexander M Lesokhin
Journal: Blood
Blood (2022) 140 (Supplement 1): 391–393.
https://doi.org/10.1182/blood-2022-162440
Published: 2022
Journal Articles

Magnetismm-3: An Open-Label, Multicenter, Non-Randomized Phase 2 Study of Elranatamab (PF-06863135) in Patients with Relapsed or Refractory Multiple Myeloma

Alexander Lesokhin, Shinsuke Iida, Don Stevens, Afshin Eli Gabayan, Wei Dong Ma, Sharon Sullivan, Marc-Steffen Raab
Journal: Blood
Blood (2021) 138 (Supplement 1): 1674.
https://doi.org/10.1182/blood-2021-152984
Published: 2021
Journal Articles

Population Pharmacokinetic Modeling of BeneFIX in Pediatric and Adult Patients with Hemophilia B Demonstrates Weight as An Important Factor Contributing to Inter-Patient PK Variability.

Chandrasekhar Udata, PhD, Sharon Sullivan, PhD, Patrick Kelly, MD, David A. Roth, MD, Xu Meng, PhD
Journal: Blood
Blood (2008) 112 (11): 1218.
https://doi.org/10.1182/blood.V112.11.1218.1218
Published: 2008
Journal Articles

Investigator-Prescribed Prophylaxis of rFIX (BeneFIX ® ) in Children <6 Years of Age: Efficacy and Safety Outcomes.

Paul E. Monahan, MD, Raina Liesner, MD, Sharon Sullivan, PhD, Brooke Hayward, SM, Maria E. Ramirez, PhD, MPH, Patrick Kelly, MD, David A. Roth, MD
Journal: Blood
Blood (2008) 112 (11): 1221.
https://doi.org/10.1182/blood.V112.11.1221.1221
Published: 2008